Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes

Study limitation reported by the research below: “The specific IL-1β antagonist used in the inflammatory attenuation analysis is not named in the abstract — canakinumab is inferred as the most established agent in this class with T2D data, but this should be confirmed in the full text.”